# Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze

> **NCT00634504** · PHASE1 · COMPLETED · sponsor: **BTG International Inc.** · enrollment: 20 (actual)

## Conditions studied

- Osteosarcoma
- Leukemia
- Lymphoma

## Interventions

- **DRUG:** glucarpidase, high-dose methotrexate, leucovorin
- **DRUG:** high-dose methotrexate, leucovorin

## Key facts

- **NCT ID:** NCT00634504
- **Lead sponsor:** BTG International Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634504, "Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00634504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*